Literature DB >> 29196906

Perceptions and Attitudes of Cancer Patients and Caregivers Towards Enrollment in Clinical Trials in Lebanon.

Rana Salem1, Charbel Matar2, Rita Assi1, Raafat Alameddine1, Sally Temraz1, Ali Shamseddine1, Deborah Mukherji3.   

Abstract

The rates of participation in oncology clinical trials (CTs) are relatively lower in the Middle East compared to other areas in the world. Many social and cultural factors underlie the patients' reluctance to participate. To probe the knowledge, attitudes, and perceptions of patients with cancer and their caregivers regarding participation in CTs at our tertiary referral center in Lebanon, we interviewed 210 patients and caregivers visiting the outpatient clinics in the Naef Basile Cancer Institute at the American University of Beirut. A questionnaire was derived from literature and administered in Arabic. The study was approved by the Institutional Review Board (IRB). Two hundred individuals agreed to answer the questionnaire. The majority of participants (90.5%) were Lebanese with the remaining being non-Lebanese Arabs. Eighty-nine participants (45%) were aware of the concepts of CTs. Eighty-two respondents (41%) would participate in phase I CTs. Twenty-nine individuals (14.5%) agree to be enrolled in CTs with the approval of their family members only. One hundred twenty-nine subjects (64.5%) stated that they would refuse enrollment in a CT where they might receive placebo. Eighty-eight (44%) of participants considered that medical records could be reviewed for research without consent while 54% agreed that samples collected during clinical workup could be used for research without the consent of the patient. There are several social and demographic correlates for participation in CTs. Raising awareness and overcoming barriers of misconception are keys to promote participation in CTs in Lebanon.

Entities:  

Keywords:  Attitudes; Cancer; Clinical trials; Lebanon; Perceptions

Mesh:

Year:  2019        PMID: 29196906     DOI: 10.1007/s13187-017-1307-3

Source DB:  PubMed          Journal:  J Cancer Educ        ISSN: 0885-8195            Impact factor:   2.037


  16 in total

1.  Awareness and Perceptions of Clinical Trials in Cancer Patients and Their Families in Saudi Arabia.

Authors:  Shouki Bazarbashi; Anees Hassan; Ahmed Mohi Eldin; Hussein Soudy; Fazal Hussain
Journal:  J Cancer Educ       Date:  2015-12       Impact factor: 2.037

2.  Prevalence of aging population in the Middle East and its implications on cancer incidence and care.

Authors:  R R Hajjar; T Atli; Z Al-Mandhari; M Oudrhiri; L Balducci; M Silbermann
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

3.  Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials.

Authors:  Primo N Lara; Debora A Paterniti; Christine Chiechi; Corinne Turrell; Claudia Morain; Nora Horan; Lisa Montell; Jose Gonzalez; Sharon Davis; Ari Umutyan; Cynthia L Martel; David R Gandara; Ted Wun; Laurel A Beckett; Moon S Chen
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

4.  Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.

Authors:  Anneke T Schroen; Gina R Petroni; Hongkun Wang; Robert Gray; Xiaofei F Wang; Walter Cronin; Daniel J Sargent; Jacqueline Benedetti; Donald L Wickerham; Benjamin Djulbegovic; Craig L Slingluff
Journal:  Clin Trials       Date:  2010-07-01       Impact factor: 2.486

5.  American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

Authors:  Lee M Ellis; David S Bernstein; Emile E Voest; Jordan D Berlin; Daniel Sargent; Patricia Cortazar; Elizabeth Garrett-Mayer; Roy S Herbst; Rogerio C Lilenbaum; Camelia Sima; Alan P Venook; Mithat Gonen; Richard L Schilsky; Neal J Meropol; Lowell E Schnipper
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

6.  Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials.

Authors:  T Godskesen; M G Hansson; P Nygren; K Nordin; U Kihlbom
Journal:  Eur J Cancer Care (Engl)       Date:  2014-01-28       Impact factor: 2.520

Review 7.  A systematic review of the factors influencing African Americans' participation in cancer clinical trials.

Authors:  Desiree Rivers; Euna M August; Ivana Sehovic; B Lee Green; Gwendolyn P Quinn
Journal:  Contemp Clin Trials       Date:  2013-04-01       Impact factor: 2.226

8.  PARTAKE survey of public knowledge and perceptions of clinical research in India.

Authors:  Tal Burt; Savita Dhillon; Pooja Sharma; Danish Khan; Deepa Mv; Sazid Alam; Sarika Jain; Bhavana Alapati; Sanjay Mittal; Padam Singh
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

9.  How Health Professionals Conceptualize and Represent Placebo Treatment in Clinical Trials and How Their Patients Understand It: Impact on Validity of Informed Consent.

Authors:  Pascal-Henri Keller; Olivier Grondin; François Tison; Francois Gonon
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

10.  Knowledge, Attitudes and Perceptions of Saudis towards Participating in Clinical Trials.

Authors:  Mohamad A Al-Tannir; Nahid El-Bakri; Amani K Abu-Shaheen
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

View more
  3 in total

1.  Motivators and barriers towards clinical research participation: A population-based survey from an Arab MENA country.

Authors:  Kamal M Al-Shami; Wesam S Ahmed; Karem H Alzoubi
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

2.  Perceptions and attitudes toward participation in clinical research in the Eastern Mediterranean Region: A systematic review.

Authors:  Mohamed Aabdien; Ibtihal Abdallah; Mohamed Iheb Bougmiza; Timo Siepmann; Ben Illigens
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

3.  Research Capacity and Training Needs for Cancer in Conflict-Affected MENA Countries.

Authors:  Zahi Abdul-Sater; Elsa Kobeissi; Marilyne Menassa; Talar Telvizian; Deborah Mukherji
Journal:  Ann Glob Health       Date:  2020-11-06       Impact factor: 2.462

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.